Company Filing History:
Years Active: 1981
Title: The Innovative Contributions of Lars-Ake Fransson
Introduction
Lars-Ake Fransson is a notable inventor based in Lund, Sweden, recognized for his contributions to the field of pharmaceuticals. He has made significant strides in the development of heparin fragments that have selective anticoagulation activity, showcasing his expertise and innovative spirit.
Latest Patents
Fransson holds a patent for "Heparin fragments having selective anticoagulation activity." This patent describes heparin fragments consisting of 14-18 sugar units, where the disaccharide unit L-iduronosyl-2-O-sulphate-N-sulpho-U-glucosamine-6-O-sulphate serves as the primary component. Notably, this particular heparin fragment includes unsulphated L-iduronic acid positioned 3-5 sugar units from the unreducing terminal. The patent also covers pharmaceutical compositions that incorporate these heparin fragments and outlines processes for their preparation.
Career Highlights
Fransson is associated with Kabi AB, a company well-regarded in the pharmaceutical industry. His work primarily focuses on developing innovative anticoagulants, which are vital for managing various medical conditions involving blood coagulation.
Collaborations
Throughout his career, Lars-Ake Fransson has collaborated with esteemed colleagues, including Ulf P Lindahl and Gudrun E Backstrom. These collaborations have significantly contributed to advancements in the understanding and application of heparin and its derivatives in pharmaceutical formulations.
Conclusion
With one patent to his name, Lars-Ake Fransson stands as a testament to innovation in the pharmaceutical sector. His work not only aids in advancing medicine but also showcases the impact of dedicated research and collaboration in the development of effective therapies. The continuous exploration of anticoagulants remains critical, and Fransson's contributions will undoubtedly influence future breakthroughs in this field.